Rising Prevalence Of Copd Fuels Growth In The Nontuberculous Mycobacterial Infection Market: Powering Innovation and Expansion in the Nontuberculous Mycobacterial Infection Market by 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts

What Is the Expected CAGR for the Nontuberculous Mycobacterial Infection Market Through 2025?
There has been a substantial expansion in the market size for nontuberculous mycobacterial infection in the recent past. The market, which is projected to increase from $14.25 billion in 2024 to $15.11 billion in 2025, is expected to have a compound annual growth rate (CAGR) of 6.0%. Enhanced diagnostic procedures, an uptick in an aging populace, heightened awareness about cystic fibrosis, and the use of immunosuppressant drugs can be credited for the growth experienced in the historical period.

What's the Projected Size of the Global Nontuberculous Mycobacterial Infection Market by 2029?
In the coming years, the nontuberculous mycobacterial infection market is predicted to experience significant expansion, escalating to a worth of $19.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. This expected increase corresponds to developments in antimicrobial drugs, enhanced awareness of ntm, breakthroughs in genetic studies, as well as telehealth and remote monitoring. The future trends driving this predicted growth include personalized medicine, regulatory emphasis, combination treatment strategies, and the use of digital health technologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/nontuberculous-mycobacterial-infection-global-market-report

Top Growth Drivers in the Nontuberculous Mycobacterial Infection Industry: What's Accelerating the Market?
The escalating incidence of chronic obstructive pulmonary disease (COPD) is predicted to fuel the expansion of the nontuberculous mycobacterial infection market. COPD is a lasting respiratory disorder distinguished by continuous and often escalating lung airflow restriction. Nontuberculous mycobacterial (NTM) infections among COPD patients results in a notable decrease in forced expiratory volume in one second (FEV1) with an augmented exacerbation rate. COPD can deteriorate the immune system and impair the lung tissue, facilitating NTM bacteria to invade the lungs. For example, a March 2023 report by The Scottish Public Health Observatory (ScotPHO) noted a rise in COPD rates between 2021 and 2022, with male rates surging from 83.2 to 97.6 per 100,000 individuals and female rates escalating from 72.6 to 97.3. Consequently, the increasing incidence of COPD is boosting the nontuberculous mycobacterial infection market. The growth curve of the nontuberculous mycobacterial infection market is anticipated to steepen with the rising prevalence of infectious diseases. These diseases, instigated by pathogenic microorganisms like bacteria, viruses, fungi, or parasites, can spread from person to person and cause a range of symptoms and health issues. The mounting prevalence of infectious diseases, including those that could lead to NTM infections, could potentially spur the NTM infection market by increasing awareness, promoting more frequent diagnostics and early detection, stimulating research and development for NTM treatments, and evoking a greater demand for NTM-targeted therapies due to an intensified healthcare focus on infectious diseases. For instance, according to the United Nations International Children's Emergency Fund (UNICEF) in November 2024, pneumonia was the most common infectious disease leading to the demise of over 700,000 children annually, approximately 2,000 deaths daily. Hence, the escalating prevalence of infectious diseases is vital for the growth of the nontuberculous mycobacterial infection market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13020&type=smp

What Trends Will Shape the Nontuberculous Mycobacterial Infection Market Through 2029 and Beyond?
Top firms engaged in the nontuberculous mycobacterial infection market are adopting contemporary approval practices for treatments, including the Fast Track designation protocol for drug endorsement to maintain their market standing. The Fast Track designation, a procedure initiated by the FDA, is intended to accelerate the development and scrutiny of drugs for serious health issues which lack adequate medical treatments. For instance, in July 2022, the U.S. federal agency, the Food and Drug Administration, accorded Fast Track designation to NUZYRA for the treatment of nontuberculous mycobacterial (NTM) lung illness caused by Mycobacterium avium complex (MAC). NUZYRA (omadacycline) is an innovative broad-spectrum antibiotic designed to tackle severe bacterial infections, inclusive of those propagated by resistant strains. This recognition allows for accelerated development and review procedures for the NUZYRA antibiotic, which is significant for addressing substantial unmet medical requirements.

What Are the Main Segments in the Nontuberculous Mycobacterial Infection Market?
The nontuberculous mycobacterial infection market covered in this report is segmented -

1) By Drug Class: Macrolides, Rifampin, Aminoglycoside, Other Drug Classes
2) By Route Of Administration: Oral, Parenteral, Other Routes
3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:
1) By Macrolides: Azithromycin, Clarithromycin
2) By Rifampin: Rifampin, Rifabutin
3) By Aminoglycoside: Amikacin, Streptomycin
4) By Other Drug Classes: Ethambutol, Clofazimine, Linezolid

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=13020&type=smp

Which Top Companies are Driving Growth in the Nontuberculous Mycobacterial Infection Market?
Major companies operating in the nontuberculous mycobacterial infection market are Pfizer Inc., Johnson & Johnson, F. Hoffman La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca PLC, Abbott Laboratories, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Astellas Pharma Inc., Vertex Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Horizon Therapeutics PLC, Lupin Limited, BioMarin Pharmaceutical Inc., Ionis Pharmaceuticals Inc., Insmed Incorporated, Paratek Pharmaceuticals Inc., Spero Therapeutics Inc., Aradigm Corporation, Dauntless Pharmaceuticals Inc., Validus Pharmaceuticals LLC.

Which Regions Will Dominate the Nontuberculous Mycobacterial Infection Market Through 2029?
North America was the largest region in the nontuberculous mycobacterial infection market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in nontuberculous mycobacterial infection market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13020

"This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work."

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.